MarketPulse

FDA Breakthrough Therapy

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Gears Up for Pivotal 2026 With Six Major Clinical Readouts Planned

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.
OCSOCSAWclinical trialsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley's BPL-003 Shows Durable Antidepressant Benefits in Treatment-Resistant Depression

AtaiBeckley's BPL-003 nasal spray demonstrates rapid and sustained antidepressant effects in treatment-resistant depression Phase 2a trial, advancing toward Phase 3 launch in Q2 2026.
ATAIPhase 3 clinical trialtreatment-resistant depression
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Optic Neuritis Data as Privosegtor Advances to Pivotal Trials

Oculis presents Phase 2 ACUITY trial results for Privosegtor at neuro-ophthalmology conference, showing vision improvements. Breakthrough therapy advances to registrational PIONEER program.
OCSOCSAWPrivosegtoroptic neuritis